Evidence map›Paper›PMID 34593488›Full record

ArticleBMJ open2021

Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS).

Thokozile R Malaba, Landon Myer, Clive Gray, Marie-Louise Newell

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Methodological Considerations for Preterm Birth Research.Frontiers in global women's health · 2021
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Thokozile R MalabaDivision of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town Faculty of Health Sciences, Observatory, South Africa thoko.malaba@uct.ac.za.ORCID 0000-0003-0938-5587
Landon MyerDivision of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town Faculty of Health Sciences, Observatory, South Africa.
Clive GrayDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town Faculty of Health Sciences, Observatory, South Africa.
Marie-Louise NewellInstitute for Developmental Science, University of Southampton Faculty of Medicine, Southampton, UK.
University of Cape Town · ZAUniversity of Southampton · GB

Funding

ART and risk of preterm delivery in a rural high HIV prevalence areaR01HD080385 · NICHD · UNIVERSITY OF SOUTHAMPTON · PI NEWELL, MARIE-LOUISE HENRICAFERNANDE · 2014 to 2019
$1.8M
NICHD NIH HHS R01 HD080385
6 · The paper itself

Abstract

purposePrematurity Immunology in Mothers living with HIV and their infants Study (PIMS) is a prospective cohort study in South Africa investigating the association between antiretroviral therapy (ART) use, preterm delivery (PTD) and small-for-gestational age (SGA) live births. PIMS main hypotheses are that ART initiation in pregnancy and ART-induced hypertension are associated with PTD and SGA respectively and that reconstitution of cellular immune responses in women on ART from before pregnancy results in increases in PTD of GA infants.

participantsPregnant women (n=3972) aged ≥18 years regardless of HIV status recruited from 2015 to 2016 into the overall PIMS cohort (2517 HIV-negative, 1455 living with HIV). A nested cohort contained 551 women living with HIV who were ≤24 weeks' GA on ultrasound: 261 initiated ART before pregnancy, 290 initiated during the pregnancy. FINDINGS TO DATE: Women in the overall cohort were followed antenatally through to delivery using routine clinical records; further women in the nested cohort were actively followed up until 12 months post partum, with data collected on maternal health (HIV care and ART use, clinical care and intercurrent clinical history). Other procedures conducted on the nested cohort included physical examinations (anthropometry, blood pressure measurement), assessment of fetal growth (ultrasound), maternal and infant phlebotomy for storage of plasma, RNA and peripheral blood mononuclear cells, collection of delivery specimens (placenta and cord blood) and infant 12-month developmental assessment. Preliminary findings have contributed to our understanding of risk factors for adverse birth outcomes, and the relationship between pregnancy immunology, HIV/ART and adverse birth outcomes. FUTURE PLANS: Using specimens collected from study participants living with HIV throughout pregnancy and first year of life, the PIMS provides a valuable platform for answering a variety of research questions focused on temporal changes of immunology markers in women whose immune status is altered by HIV infection, and how ART initiated during the pregnancy affects immune responses. The relationship between these immunological changes with adverse birth outcomes as well as possible longer-term impact of exposure to ART in fetal and early life will be explored. Additionally, further active and passive follow-up of mothers and their infants is planned at school-going age and beyond to chart growth, morbidity and development, as well as changes in family circumstances.

Indexed as

HIV InfectionsPregnancy Complications, InfectiousAdolescentAdultCohort StudiesFemaleHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalLeukocytes, MononuclearMothersPregnancyProspective StudiesepidemiologyHIV & AIDSimmunologymaternal medicinepublic health

Identifiers

PMID34593488
PMCPMC8487191
OpenAlexW3203945877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.